National Advertising Division In Brief
This article was originally published in The Tan Sheet
Executive Summary
Combe ends “alarmist” tone in claims; comparative claims require more than placebo trials; use of FDA logo in ad triggers review; and Excedrin to discontinue speed claims.
You may also be interested in...
In Brief
Novartis appeals Excedrin case to NARB
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.